TC Biopharm () (TCBP)
0.46
0.01 (1.55%)
At close: Jan 14, 2025, 3:58 PM
undefined% (undefined)
| Bid | 0.44 |
| Market Cap | 5.63M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -226.5 |
| PE Ratio (ttm) | 0 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.48 |
| Volume | 734,099 |
| Avg. Volume (20D) | 1,951,009 |
| Open | 0.44 |
| Previous Close | 0.45 |
| Day's Range | 0.41 - 0.46 |
| 52-Week Range | 0.37 - 32.70 |
| Beta | undefined |
About TCBP
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom....
Industry Biotechnology
Sector Healthcare
IPO Date Feb 11, 2022
Employees 41
Stock Exchange NASDAQ
Ticker Symbol TCBP
Website https://www.tcbiopharm.com
Analyst Forecast
According to 1 analyst ratings, the average rating for TCBP stock is "Buy." The 12-month stock price forecast is $2.4, which is an increase of 426.55% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 week ago ·
Source
+3.3%
TC BioPharm shares are trading higher on possible ...
Unlock content with
Pro Subscription
4 weeks ago ·
Source
+38.59%
TC BioPharm shares are trading higher after the company's Board approved a special dividend.
